Profile data is unavailable for this security.
About the company
Pharmanutra SpA is an Italy-based company engaged in the healthcare industry. The Company develops nutraceutical products and medical devices. It focuses on studying and producing formulations that are backed up in scientific research. It is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The Company offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
- Revenue in EUR (TTM)100.32m
- Net income in EUR10.83m
- Incorporated--
- Employees111.00
- LocationPharmanutra SpAVia delle Lenze n. 216/BPISA 56122ItalyITA
- Websitehttps://www.pharmanutra.it/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medios AG | 1.81bn | 17.97m | 451.45m | 500.00 | 23.24 | 0.8907 | 11.59 | 0.2495 | 0.7615 | 0.7615 | 76.55 | 19.87 | 2.90 | 27.80 | 13.71 | 3,513,961.00 | 2.88 | 3.40 | 3.46 | 4.07 | 5.99 | 6.05 | 0.9931 | 1.01 | 2.15 | 16.94 | 0.0347 | 0.00 | 10.80 | 40.34 | 2.62 | 34.17 | -7.11 | -- |
| Theravance Biopharma Inc | 56.68m | -41.25m | 451.69m | 99.00 | -- | 2.39 | -- | 7.97 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Pharmanutra SpA | 100.32m | 10.83m | 456.46m | 111.00 | 41.76 | 7.95 | 33.39 | 4.55 | 1.13 | 1.13 | 10.43 | 5.93 | 0.9123 | 0.5233 | 4.00 | 955,428.60 | 9.85 | 18.39 | 13.20 | 24.80 | 95.92 | 96.36 | 10.79 | 17.77 | 1.87 | 34.93 | 0.3324 | 52.51 | 21.13 | 16.51 | -14.73 | 8.44 | 75.71 | 11.20 |
| Eyepoint Pharmaceuticals Inc | 46.09m | -72.71m | 459.03m | 121.00 | -- | 1.91 | -- | 9.96 | -1.83 | -1.83 | 1.17 | 5.01 | 0.2068 | 1.14 | 7.44 | 413,380.20 | -32.62 | -40.44 | -40.06 | -47.79 | 90.50 | 83.45 | -157.77 | -186.23 | 5.01 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Shanghai New World Co Ltd | 145.02m | 4.25m | 459.63m | 1.20k | 108.05 | 0.8633 | -- | 3.17 | 0.0519 | 0.0519 | 1.77 | 6.50 | 0.2026 | 4.62 | 7.42 | 951,798.10 | 0.5858 | 0.5242 | 0.78 | 0.7249 | 38.56 | 33.70 | 2.89 | 2.71 | 1.52 | -- | 0.1222 | 82.75 | 33.39 | -16.40 | 160.85 | -35.00 | 53.61 | -25.42 |
| Medincell SA | 10.85m | -26.42m | 462.55m | 138.00 | -- | -- | -- | 42.64 | -1.02 | -1.02 | 0.4086 | -0.8965 | 0.2605 | -- | 6.81 | -- | -63.46 | -- | -115.15 | -- | 60.43 | -- | -243.58 | -366.40 | -- | -4.29 | 1.69 | -- | -8.67 | 44.33 | 21.78 | -- | -- | -- |
| Clinuvel Pharmaceuticals Limited | 53.20m | 18.38m | 463.94m | 16.00 | 26.10 | 4.26 | 24.44 | 8.72 | 0.5825 | 0.5825 | 1.69 | 3.56 | 0.4693 | -0.9514 | 7.35 | -- | 16.21 | 21.25 | 18.57 | 23.55 | 109.28 | -- | 34.54 | 41.84 | 6.43 | 14.53 | 0.006 | 7.44 | 24.27 | 26.14 | 46.58 | 18.27 | 68.74 | 20.11 |
| Chengdu Olymvax Biopharmaceuticals Inc | 63.33m | -1.56m | 469.41m | 471.00 | -- | 4.14 | -- | 7.41 | -0.0303 | -0.0303 | 1.23 | 2.21 | 0.3338 | 0.4197 | 1.08 | 1,061,669.00 | -1.22 | 3.17 | -1.70 | 4.68 | 93.29 | 93.00 | -3.64 | 7.44 | 1.92 | -3.90 | 0.2505 | 9.82 | -9.38 | 45.40 | -33.94 | -- | 56.47 | -- |
| Soho Global Health Tbk PT | 487.94m | 25.04m | 472.53m | 2.32k | 18.87 | 3.29 | 16.33 | 0.9684 | 34.71 | 34.71 | 676.37 | 198.99 | 1.77 | 5.67 | 4.97 | 3,617,495,000.00 | 9.06 | 7.97 | 16.53 | 14.37 | 16.24 | 19.39 | 5.13 | 4.65 | 1.26 | -- | 0.006 | -- | 12.45 | 12.43 | 4.10 | 49.70 | 21.21 | -- |
Data as of Jul 23 2024. Currency figures normalised to Pharmanutra SpA's reporting currency: Euro EUR
12.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 08 Jan 2024 | 334.58k | 3.46% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 May 2023 | 211.58k | 2.19% |
| Danske Bank A/S (Investment Management)as of 30 Jun 2024 | 174.63k | 1.80% |
| Cr�dit Mutuel Asset Management SAas of 29 Dec 2023 | 100.00k | 1.03% |
| Arca Fondi SGR SpAas of 28 Jun 2024 | 97.71k | 1.01% |
| Euromobiliare Asset Management SGR SpAas of 28 Jun 2024 | 66.00k | 0.68% |
| Amundi Asset Management SA (Investment Management)as of 03 Jul 2024 | 59.75k | 0.62% |
| Mediolanum Gestione Fondi SGRpAas of 29 Dec 2023 | 59.00k | 0.61% |
| Kairos Partners SGR SpAas of 30 Jun 2023 | 58.35k | 0.60% |
| Pharus Asset Management SAas of 31 Dec 2023 | 47.50k | 0.49% |
More ▼
Data from 29 Dec 2023 - 17 Jul 2024Source: FactSet Research Systems Inc.
